Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...